Search tips
Search criteria 


Logo of jurbhealthspringer.comThis journalToc AlertsSubmit OnlineOpen ChoiceThis journal
J Urban Health. 2003 June; 80(2): 274–287.
PMCID: PMC3456282

Drug-related mortality and fatal overdose risk: Pilot cohort study of heroin users recruited from specialist drug treatment sites in London


Fatal overdose and drug-related mortality are key harms associated with heroin use, especially injecting drug use (IDU), and are a significant contribution to premature mortality among young adults. Routine mortality statistics tend to underreport the number of overdose deaths and do not reflect the wider causes of death associated with heroin use. Cohort studies could provide evidence for interpreting trends in routine mortality statistics and monitoring the effectiveness of strategies that aim to reduce drug-related deaths. We aimed to conduct a retrospective mortality cohort study of heroin users recruited from an anonymous reporting system from specialist drug clinics. Our focus was to test whether (1) specialist agencies would agree to participate with a mortality cohort study, (2) a sample could be recruited to achieve credible estimates of the mortality rate, and (3) ethical considerations could be met. In total, 881 heroin users were recruited from 15 specialist drug agencies. The overall mortality rate of the cohort of heroin users was 1.6 (95% confidence interval [CI], 1.1 to 2.2.) per 100 person-years. Mortality was higher among males, heroin users older than 30 years, and injectors, but not significantly higher after adjustment in a Cox proportional hazard model. Among the 33 deaths, 17 (52%) were certified from a heroin/methadone or opiate overdose, 4 (12%) from drug misuse, 4 (12%) unascertained, and 8 (24%) unrelated to acute toxic effects of drug use. Overall, the overdose mortality rate was estimated to be at least 1.0 per 100 person-years. The standardized mortality ratio (SMR) was 17 times higher for female and male heroin users in the cohort compared to mortality in the non-heroin-using London population aged 15–59 years. The pilot study showed that these studies are feasible and ethical, and that specialist drug agencies could have a vital role to play in the monitoring of drug-related mortality.

Full Text

The Full Text of this article is available as a PDF (92K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Darke S, Zador D. Fatal heroin overdose: a review. Addiction. 1996;91:1765–1772. doi: 10.1111/j.1360-0443.1996.tb03800.x. [PubMed] [Cross Ref]
2. Law M, Lynskey M, Ross J, Hall W. Back-projection estimates of the number of dependent heroin users in Australia. Addiction. 2001;96:433–443. doi: 10.1046/j.1360-0443.2001.9634337.x. [PubMed] [Cross Ref]
3. Tackling Drugs to Build a Better Britain: the Government’s 10 Year Strategy for Tackling Drug Misuse. London, England: Her Majesty’s Stationery Office; 1998.
4. Hulse GK, English DR, Milne E, Holman DJ. The quantification of mortality resulting from the regular use of illicit opiates. Addiction. 1999;94:221–229. doi: 10.1046/j.1360-0443.1999.9422216.x. [PubMed] [Cross Ref]
5. Reducing Drug Related Deaths. London, England: Home Office; 2000.
6. Hickman M, Madden P, Henry J, et al. Trends in drug overdose deaths in England and Wales 1993–98: does methadone kill more drug users than heroin? Addiction. 2003;98:419–426. doi: 10.1046/j.1360-0443.2003.00294.x. [PubMed] [Cross Ref]
7. Griffiths C, Brock A, Mickleburgh M. Deaths related to drug poisoning: results for England and Wales, 1993 to 2000. Natl Stat Q. 2002;13:76–81.
8. Hickman M, Shuying S, De Angelis D. Estimating long-term trends in the incidence and prevalence of injecting drug use (IDU) and the number of ex-IDU: the use of opiate overdose deaths and back-calculation methods [abstract]. International Harm Reduction Conference; April 6–10, 2003; Chiang Mai, Northern Thailand.
9. Neeleman J, Farrell M. Fatal methadone and heroin overdoses: time trends in England and Wales. J Epidemiol Community Health. 1997;51:435–437. doi: 10.1136/jech.51.4.435. [PMC free article] [PubMed] [Cross Ref]
10. Uren Z. Geographical variations in deaths related to drug misuse in England and Wales, 1993–99. Natl Stat. 2001;January:25–35.
11. Joe G, Simpson D. Mortality rates among opioid addicts in a longitudinal study. Am J Public Health. 1987;77:347–348. [PubMed]
12. Frischer M, Goldberg D, Rahman M, Berney L. Mortality and survival among a cohort of drug injectors in Glasgow, 1982–1994. Addiction. 1997;92:419–427. doi: 10.1111/j.1360-0443.1997.tb03373.x. [PubMed] [Cross Ref]
13. Perucci CA, Davoli M, Rapiti E, Abeni DD, Forastiere F. Mortality of intrayenous drug users in Rome: a cohort study. Am J Public Health. 1991;81:1307–1310. doi: 10.2105/AJPH.81.10.1307. [PubMed] [Cross Ref]
14. Oppenheimer E, Tobutt C, Taylor C, Andrew T. Death and survival in a cohort of heroin addicts from London clinics: a 22 year follow-up study. Addiction. 1994;89:1299–1308. doi: 10.1111/j.1360-0443.1994.tb03309.x. [PubMed] [Cross Ref]
15. Orti RM, Domingo-Salvany A, Munoz A, Macfarlane D, Suelves JM, Anto JM. Mortality trends in a cohort of opiate addicts, Catalonia, Spain. Int J Epidemiol. 1996;25:545–553. [PubMed]
16. Davoli M, Perucci CA, Rapiti E, et al. A persistent rise in mortality among injection drug users in Rome, 1980 through 1992. Am J Public Health. 1997;87:851–853. [PubMed]
17. Quaglio G, Talamini G, Lechi A, Venturini L, Lugoboni F, Mezzelani P. Study of 2,708 heroin-related deaths in North Eastern Italy 1985–98 to establish the main causes of death. Addiction. 2001;96:1127–1137. doi: 10.1046/j.1360-0443.2001.96811276.x. [PubMed] [Cross Ref]
18. McGinnis JM, Foege WH. Mortality and morbidity attributable to use of addictive substances in the United States. Proc. Assoc Am Phys. 1999;3:109–118. doi: 10.1046/j.1525-1381.1999.09256.x. [PubMed] [Cross Ref]
19. Ghodse AH, Sheehan M, Taylor C, Edwards G. Deaths of drug addicts in the United Kingdom 1967–81. BMJ. 1985;290:425–428. doi: 10.1136/bmj.290.6466.425. [PMC free article] [PubMed] [Cross Ref]
20. Ghodse H, Oyefeso A, Kilpatrick B. Mortality of drug addicts in the United Kingdom, 1967–1993. Int J Epidemiol. 1998;27:473–478. doi: 10.1093/ije/27.3.473. [PubMed] [Cross Ref]
21. Hickman M, Griffin M, Mott J, et al. Can the epidemiological function of the Addicts Index be continued-evidence from matching the Home Office Addicts Index with the Drug Misuse Database (DMD). Drugs Educ Prev Policy. In press.
22. Hickman M, Sutcliffe A, Sondhi A, Stimson G. Surveillance of problem drug use in the UK: a review of a regional drug misuse database. J Public Health. 1999;21:271–277.
23. Devis T, Rooney C. The time taken to register a death. Popul Trends. Summer 1997: 48–55.
24. Bland M. An Introduction to Medical Statistics. 2nd ed. Oxford, UK: Oxford University Press; 1995.
25. Baker A. ONS drug-related deaths database: first results for England and Wales, 1993–97. Health Stat Q. 2000;5:57–60.
26. Stimson GV, Oppenheimer E. Heroin Addiction: Treatment and Control. London, England: Tavistock; 1982.
27. Griffiths P, Gossop M, Powis B, Strang J. Transitions in patterns of heroin administration: a study of heroin chasers and heroin injectors. Addiction. 1994;89:301–309. doi: 10.1111/j.1360-0443.1994.tb00896.x. [PubMed] [Cross Ref]
28. Caplehorn JR, Dalton MS, Cluff MC, Petrenas AM. Retention in methadone maintenance and heroin addicts’ risk of death. Addiction. 1994;89:203–209. doi: 10.1111/j.1360-0443.1994.tb00879.x. [PubMed] [Cross Ref]
29. Caplehorn JR, Dalton MS, Haldar F, Petrenas AM, Nisber JG. Methadone maintenance and addicts’ risk of fatal heroin overdose. Subst Use Misuse. 1996;31:177–196. [PubMed]
30. White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction. 1999;94:961–972. doi: 10.1046/j.1360-0443.1999.9479612.x. [PubMed] [Cross Ref]
31. Warner-Smith M, Darke S, Lynskey M, Hall W. Heroin overdose: causes and consequences. Addiction. 2001;96:1113–1125. doi: 10.1046/j.1360-0443.2001.96811135.x. [PubMed] [Cross Ref]
32. Gossop M, Stewart D, Treacy S, Marsden J. A prospective study of mortality among drug misusers during a 4-year period after seeking treatment. Addiction. 2002;97:39–47. doi: 10.1046/j.1360-0443.2002.00079.x. [PubMed] [Cross Ref]
33. Draft Guidance: Use and Disclosure of Medical Data. Wilmslow, UK: Office of the Information Commissioner; 2001.
34. Gostin LO. Public Health Law: Power, Duty, Restraint. Berkeley, CA: University of California Press; 2001.
35. Personal Information in Medical Research. London, England: Medical Research Council; 2000.

Articles from Journal of Urban Health : Bulletin of the New York Academy of Medicine are provided here courtesy of New York Academy of Medicine